What tech stack does Johnson & Johnson use?

J&J's primary cloud platform is Microsoft Azure, consistent with the company's enterprise Microsoft relationship and Azure's strength in regulated healthcare and life sciences workloads. CIO Jim Swanson — who leads more than 4,000 IT professionals across 50 countries — has publicly emphasized a cloud-first infrastructure strategy. Backend services are built primarily in Java (historically dominant in pharma enterprise IT), Python (increasingly central to data science and AI/ML pipelines), Node.js (API and microservices layer), and SQL for relational database work.

For CI/CD, J&J relies on Jenkins pipelines with Bitbucket for source control and SonarQube for automated code quality checks. Oracle EBS underpins core finance, ERP, and supply chain management across the enterprise. Apex Analytix FirstStrike handles accounts payable automation. All major system implementations require GxP validation documentation under FDA 21 CFR Part 11 and EU Annex 11 requirements — extending deployment timelines significantly compared to non-regulated enterprises and creating high switching costs once a vendor is qualified and embedded.

The data stack is modern and cloud-native: Snowflake serves as the enterprise data warehouse, Databricks handles large-scale data engineering and ML model training, and dbt manages data transformation pipelines. Tableau is the primary business intelligence and visualization layer across the enterprise. This Modern Data Stack is consistent with J&J's investments in data-driven commercial analytics, clinical trial data management, and AI-assisted drug discovery.

For people operations, J&J runs a global Workday HCM deployment covering payroll, benefits, performance management, onboarding, and learning across multiple countries. On the commercial side, life sciences CRM is in active evolution — Veeva is the industry standard for pharma commercial suites and is widely used in J&J's Innovative Medicine commercial organization. J&J also runs IoT platforms for manufacturing, including a TCS-partnered project for Acuvue contact lens manufacturing. On GenAI, CIO Swanson announced in 2025 that J&J had deliberately narrowed its generative AI projects to focus on tangible, high-impact use cases after extensive piloting, suggesting a procurement posture that favors proven ROI over experimentation.

J&J's Azure-first cloud posture makes it a natural target for Microsoft ecosystem vendors — Copilot for enterprise productivity, Azure AI Services, Azure OpenAI for drug discovery workflows, and Microsoft Purview for compliance data governance are all active conversation areas in large pharma. The Snowflake and Databricks combination signals a mature data platform team actively evaluating AI/ML vendors for drug discovery acceleration, clinical trial analytics, and commercial forecasting models.

For displacement opportunities: Oracle EBS is aging, and J&J — with the DePuy Synthes separation creating a net-new standalone IT environment — is a candidate for ERP modernization at the separating entity. Workday HCM is deeply embedded and unlikely to be displaced in the near term. The 2023–2027 period of structural change (Kenvue spin complete, DePuy Synthes separation underway) creates net-new carve-out IT projects at each separating entity — ERP, identity management, integration middleware, HR, and procurement platforms all require net-new purchasing decisions. Build-vs-buy posture leans strongly toward buy for standard enterprise functions and toward internal build for proprietary scientific data platforms and competitive drug discovery tools.